ClinicalTrials.gg
WithdrawnNCT03343678Updated Jan 9, 2018

This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax

A Phase 1 interventional study of Venetoclax and BI 836826 in Leukemia, Lymphocytic, Chronic, B-Cell, sponsored by Boehringer Ingelheim. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-01-09.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Why this study was withdrawn
Company strategic decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Ages
18 Years and older
Sex
All
01

Study summary

The main objective of this trial is to determine the maximum tolerated dose (MTD) of BI 836826 in combination with venetoclax on the basis of dose limiting toxicities (DLTs incidence rate during the MTD evaluation period of the combination treatment and to determine the recommended Phase II dose (RP2D) of the combination.

Other objectives are to evaluate the pharmacokinetics of BI 836826 in combination with venetoclax and to further determine the safety, as well as to evaluate the efficacy of the combination by means of the Complete Response (CR) rate and Minimal Residual Disease (MRD) negativity rate.

02

Conditions studied

  • Leukemia, Lymphocytic, Chronic, B-Cell
03

In context

Leukemia, Lymphocytic, Chronic, B-Cell

2,038 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Chronic Lymphocytic Leukaemia (CLL) according to International Workshop for Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria documented in medical records
  • Indication for treatment of CLL based on investigator's assessment consistent with accepted IWCLL criteria
  • CLL after standard therapy in line with the following requirements:

    • Presence of TP53 (Tumour Protein) mutation or deletion (17p), AND at least one prior therapy for CLL with a B-cell receptor pathway inhibitor or to the prescription of a B-cell receptor pathway inhibitor OR
    • Absence of TP53 mutation or deletion (17p) AND at least 2 prior treatment regimens for CLL including:

      • at least 4 cycles of chemo-immunotherapy containing a CD20-targeting monoclonal antibody, i.e. at least 4 doses of a monoclonal antibody and at least 4 doses of a cytotoxic AND
      • a B-cell receptor pathway inhibitor
  • Clinically quantifiable disease burden defined as

    • either Absolute Lymphocyte Count (ALC) >10x10\^9/L, or
    • measurable lymphadenopathy (at least one node > 2 cm on Computed Tomography (CT) scan) or
    • quantifiable bone marrow infiltration documented in a bone marrow during screening if applicable
  • Resolution of all acute non-hematologic toxic effects of any prior antitumour therapy to Grade \<=1 with the exception of alopecia or neurotoxicity (Grade 1 or 2 neurotoxicity permitted) prior to the first dose of venetoclax
  • (ECOG) performance score of 0, 1 or 2
  • Patient of full age (according to local legislation, usually >= 18 years) at screening.
  • Male or female patients. Women of (WOCBP) and men able to father a child must be ready and able to use highly effective methods of per International Conference on Harmonisation (ICH) M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information.
  • Signed and dated written in accordance with International Conference on Harmonisation - Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial

Exclusion criteria

Exclusion criteria:

  • Known transformation of Chronic Lymphocytic Leukaemia (CLL) to an aggressive B-cell at the time of screening (e.g. large B-cell lymphoma, Richter's syndrome)
  • History of a non-CLL malignancy except for the following:

    • adequately treated local basal cell or squamous cell carcinoma of the skin,
    • cervical carcinoma in situ,
    • superficial bladder cancer,
    • asymptomatic prostate cancer without known disease and with no requirement for therapy or requiring only hormonal therapy and with normal prostate-specific antigen for >=1 year prior to enrolment,
    • other adequately treated Stage 1 or 2 cancer currently in complete response,
    • or any other cancer that has been in complete response for >=2 years.
  • Ongoing systemic therapy other than
  • Previous treatment with a CD37-targeting antibody or antibody drug conjugate
  • \< 1 x 10\^9/L
  • count \< 50 x 10\^9/L
  • (AST) and/or Alanine Transaminase (ALT) > 3 times the (ULN) range
  • > 1.5 time ULN range with the exception of known Gilbert's syndrome
  • Estimated (GFR) \<30 mL/min/1.73m2 (based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula)
  • (HIV) infection
  • Active infection (defined as presence of Hep B DNA), active infection (defined as presence of Hep C RNA). (Note: Laboratory tests performed as routine procedure prior to signing ICF but within 2 weeks prior to Cycle 1 Day 1 may be used).
  • Cytomegalovirus (CMV) viraemia (Note: Laboratory tests performed as routine procedure prior to signing Form (ICF) but within 2 weeks prior to Cycle 1 Day 1 may be used).
  • Active bacterial, viral, or fungal infection requiring systemic treatment.
  • Other concomitant illness, medical condition, surgical history, physical finding, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia requiring therapy (with the exception of extrasystoles or minor conduction abnormalities), (ECG) finding, or laboratory abnormality that in the investigator's opinion could potentially adversely affect the safety of the patient or impair the assessment of trial results
  • Known or suspected to the trial medications or
  • Known allergy to xanthine oxidase inhibitors and/or rasburicase in patients at risk of Tumour Lysis Syndrome (TLS)
  • Prior treatment with a BCL2i (B-Cell Lymphoma-2 protein) unless the patient has started venetoclax treatment and is still in the ramp-up phase
  • Use of a strong inhibitor (e.g., ketoconazole, ritonavir, clarithromycin, itraconazole, voriconazole, posaconazole) or of a moderate CYP3A inhibitor (e.g., erythromycin, ciprofloxacin, diltiazem, fluconazole, verapamil), use of a strong CYP3A inducer (e.g., carbamazepine, phenytoin, rifampicin) or a moderate CYP3A inducer (e.g., bosentan, efavirenz, etravirine, modafinil, nafcillin) within five times the half-life of the drug before the initiation of the venetoclax ramp-up period
  • Use of a Permeability GlycoProtein (P-gp) inhibitor (e.g., rifampicin) or a breast cancer resistance protein (BCRP) inhibitor within five times the half-life of the drug before the initiation of the venetoclax ramp-up period
  • Women who are pregnant, breastfeeding, or who plan to become pregnant while in the trial
  • Patients unable to comply with protocol
  • Persons with any kind of dependency on the investigator or employed by the sponsor or investigator
  • Patients who are under judicial protection and patients who are legally institutionalized
  • Concomitant participation to a non-CLL device or drug trial or within 30 days after end of participation
  • Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial patient or unlikely to complete the trial
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Venetoclax + BI 836826

    Drug: Venetoclax · Drug: BI 836826

Interventions

  • Venetoclax given alone and then in combination with BI 836826

  • Venetoclax given in combination with BI 836826

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD) based on the number of patients with dose limiting toxicities (DLTs) in the MTD evaluation period

    Time frame: up to 28 days

  2. Number of patients with dose limiting toxicities (DLTs) in the Maximum tolerated dose (MTD) evaluation period

    Time frame: up to 28 days

Secondary outcomes

  1. Area under the plasma concentration-time curve at steady-state (AUCtau) of BI 836826 when administered in combination with venetoclax with an observation time of 28 days in Cycle 1 of the combination.

    Time frame: up to 28 days

  2. Complete response (CR) defined by investigator's assessment based on response assessment at imaging time points, analysed by complete response rate

    Time frame: up to 36 months

  3. Minimal residual disease (MRD) negativity based on blood and analysed by MRD negativity rate

    Time frame: up to 36 months

  4. Minimal residual disease (MRD) negativity based on bone marrow and analysed by MRD negativity rate

    Time frame: up to 36 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2018; primary completion for May 2018, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2017
First posted
Nov 17, 2017
StartEst.
Jan 17, 2018
Primary completionEst.
May 25, 2018
CompletionEst.
Nov 25, 2020
Last update
Jan 9, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03343678
Responsible party
Sponsor
First posted
Nov 17, 2017
Start date
Jan 17, 2018 (estimated)
Primary completion
May 25, 2018 (estimated)
Completion
Nov 25, 2020 (estimated)
Last update
Jan 9, 2018

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BI 836826

Start the discussion